LBX Pharmacy - Public Comps and Valuation Multiples

LBX Pharmacy Overview

About LBX Pharmacy

LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.

Founded

2005

HQ

Employees

n/a

Website

lbxdrugs.com

Sectors

Pharmacies

Financials

LTM Revenue $3.2B

LTM EBITDA $319M

EV

$2.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

LBX Pharmacy Financials

As of August 2025, LBX Pharmacy reported last 12-month revenue of $3.2B and EBITDA of $319M.

In the same period, LBX Pharmacy generated $1.1B in LTM gross profit and $96.2M in net income.

See LBX Pharmacy valuation multiples based on analyst estimates

LBX Pharmacy P&L

In the most recent fiscal year, LBX Pharmacy reported revenue of $3.1B and EBITDA of $360M.

LBX Pharmacy expects next 12-month revenue of XXX and NTM EBITDA of XXX

See LBX Pharmacy valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$3.2B	XXX	$3.1B	XXX	XXX	XXX
Gross Profit	$1.1B	XXX	$1.0B	XXX	XXX	XXX
Gross Margin	34%	XXX	33%	XXX	XXX	XXX
EBITDA	$319M	XXX	$360M	XXX	XXX	XXX
EBITDA Margin	10%	XXX	11%	XXX	XXX	XXX
EBIT	$170M	XXX	$169M	XXX	XXX	XXX
EBIT Margin	5%	XXX	5%	XXX	XXX	XXX
Net Profit	$96.2M	XXX	$72.8M	XXX	XXX	XXX
Net Margin	3%	XXX	2%	XXX	XXX	XXX
Net Debt	XXX	XXX	$94.5M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for LBX Pharmacy including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $3.2B. EBITDA for the last twelve months was $319M. In the most recent fiscal year, LBX Pharmacy achieved $3.1B in revenue and $360M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$3.2B	Analyst estimates available to subscribers	$3.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.1B	Analyst estimates available to subscribers	$1.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	34.0% gross margin	Analyst estimates available to subscribers	33.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$319M	Analyst estimates available to subscribers	$360M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	10.0% EBITDA margin	Analyst estimates available to subscribers	11.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$170M	Analyst estimates available to subscribers	$169M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	5.3% EBIT margin	Analyst estimates available to subscribers	5.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$96.2M	Analyst estimates available to subscribers	$72.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	3.0% net profit margin	Analyst estimates available to subscribers	2.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$94.5M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for LBX Pharmacy

This financial data table provides comprehensive performance metrics for LBX Pharmacy, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

LBX Pharmacy generated $3.2B in revenue over the last twelve months.
The company achieved $319M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.1B.
Net income over the last twelve months reached $96.2M.

Fiscal Year Performance

In the most recent fiscal year, LBX Pharmacy reported $3.1B in total revenue.
Fiscal year EBITDA was $360M.
The company maintained a gross profit margin of 33.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 11.5%.
Net profit margin reached 2.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for LBX Pharmacy. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

LBX Pharmacy Stock Performance

LBX Pharmacy has current market cap of CNY 13.2B (or $1.8B), and EV of CNY 16.0B (or $2.2B).

Market Cap Evolution

LBX Pharmacy Stock Data

As of September 15, 2025, LBX Pharmacy's stock price is CNY 17 (or $2).

See LBX Pharmacy trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.2B	$1.8B	XXX	XXX	XXX	XXX	$0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

LBX Pharmacy Valuation Multiples

LBX Pharmacy's trades at 0.7x EV/Revenue multiple, and 6.2x EV/EBITDA.

See valuation multiples for LBX Pharmacy and 15K+ public comps

LBX Pharmacy Financial Valuation Multiples

As of September 15, 2025, LBX Pharmacy has market cap of $1.8B and EV of $2.2B.

Equity research analysts estimate LBX Pharmacy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

LBX Pharmacy has a P/E ratio of 19.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.8B	XXX	$1.8B	XXX	XXX	XXX
EV (current)	$2.2B	XXX	$2.2B	XXX	XXX	XXX
EV/Revenue	0.7x	XXX	0.7x	XXX	XXX	XXX
EV/EBITDA	7.0x	XXX	6.2x	XXX	XXX	XXX
EV/EBIT	13.2x	XXX	13.3x	XXX	XXX	XXX
EV/Gross Profit	2.1x	XXX	n/a	XXX	XXX	XXX
P/E	19.2x	XXX	25.4x	XXX	XXX	XXX
EV/FCF	12.6x	XXX	10.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get LBX Pharmacy Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

LBX Pharmacy Margins & Growth Rates

LBX Pharmacy's last 12 month revenue growth is 7%

LBX Pharmacy's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

LBX Pharmacy's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

LBX Pharmacy's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for LBX Pharmacy and other 15K+ public comps

LBX Pharmacy Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	7%	XXX	6%	XXX	XXX	XXX
EBITDA Margin	10%	XXX	11%	XXX	XXX	XXX
EBITDA Growth	9%	XXX	-12%	XXX	XXX	XXX
Rule of 40	20%	XXX	19%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	28%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	28%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial